CONTIPRO (CP) has been involved in the research, development and biotechnological production of active ingredients for the cosmetic and pharmaceutical industries for over twenty two years. With excellent production quality and extensive research facilities, CP is one of the world’s leading manufacturers of hyaluronic acid and derived applications. Through its distribution networks, the holding exports 95% of its output to more than 50 countries worldwide. A recent study showed that CP currently controls 60% of the European and 30% of the world market in hyaluronan.
The research activities of CP´s laboratories concentrate on hyaluronan, nanotechnology, tissue engineering with an overlap into regenerative medicine, wound healing, the development of carriers for the targeted delivery of substances and skin ageing. Specialized teams of researchers work very closely with universities, academic institutions and commercial entities in the Czech Republic, Slovakia, France, Germany and Italy.
Role in IMMODGEL
With its advanced expertise in biomaterials, CP is in charge of the design, development and micropatterning of hydrogels. The hyaluronan-based scaffolds are designed by means of a non-cytotoxic reaction that ensures cell viability, allowing the incorporation of macrophages into the system.
CP is in charge of modifying the mechanical and viscoelastic properties of the scaffold and its surface micropatterning in order to increase the biocompatibility of the hydrogel and to optimise macrophage control as well as cytokine release. In addition, CP will supply the IMMODGEL partners with hyaluronic acid derivatives to be incorporated in the polyelectrolyte multilayer. The latter will serve as an adhesive layer between the titanium implant and the immunomodulatory hydrogel.